Mylan Inc. has announced that its U.S. based subsidiary, Mylan Pharmaceuticals has launched a generic version of Eisai Corporation’s Aciphex(R) Tablets. The generic’s name is Rabeprazole Sodium-release Tablets. The tablets are indicated for short-term treatment in the healing and symptomatic relief of both erosive or ulcerative gastroesophageal reflux disease and duodenal ulcers.
While the generic version promises to be far less costly than Aciphex, it may take a few months for Rabeprazole’s price to be significantly less than that of Aciphex…… wsj.com